Arno de Wilde’s Post

We are proud to share that updated data from the Phase 1 investigator-initiated trials in patients with progressive multiple sclerosis will be presented at the 2025 #ECTRIMS Congress in Barcelona. This encouraging data with our investigational CAR T-cell therapy, KYV-101, highlights the broader potential of our therapy within neuroimmunology-related autoimmune diseases.    Read our press release for more details on the data presentation: https://bit.ly/42GYKrH #ECTRIMS2025 #MS

People with scleroderma (also called systemic sclerosis) often develop serious lung problems. One of the most common is interstitial lung disease (ILD). Here’s what’s usually done: 📍 Diagnosis of scleroderma depends on noticing skin symptoms or positive antibodies. 📍 Doctors use pulmonary function tests (PFTs) to check for ILD. But this approach has flaws. Studies show that PFTs can miss ILD, especially early on. ILD is found in up to 80–90% of scleroderma patients by imaging or autopsy; yet only 30–40% are diagnosed early. And scleroderma can exist without visible skin thickening, making it easy to overlook. ILD from scleroderma is serious and sometimes deadly. The current standard waits for obvious signs. #Scleroderma #ILD #PulmonaryFibrosis #AutoimmuneLungDisease #EarlyDetection #ClinicalStandards #LungHealth

Screening and diagnostic approach for sarcopenia and potential therapeutic interventions associated with improvement in patients with cardiovascular disease #ageing #sarcopenia #CVD #muscle #screening https://lnkd.in/epDadJy6

Cardiovascular disease continues to place an enormous strain on healthcare systems worldwide. Coronary Artery Disease (CAD) alone is a leading cause of death and driver of significant costs to deliver timely and effective care for patients with chest pain. That’s why Roche is working with Exploris Health AG to expand access to an integrated AI-based solution that combines biomarker data with clinical information to support earlier detection of CAD to avoid heart attacks. #HealthcareInnovation #DigitalHealth #AIinHealthcare #HealthTech #CardiacCare #ClinicalAlgorithms #Diagnostics

🫀 Coronary Artery Disease (CAD) is chronic and multifactorial — not driven by a single pathway, but by a complex web of processes including inflammation, metabolism, genetics, and environment. 🔎 To reflect this complexity, we combine biomarker data with clinical information in a multi-marker AI algorithm — boosting predictive accuracy and clinical utility. 🤝 We’re proud to collaborate with Roche’s navify® to enable earlier CAD detection and help prevent heart attacks before they happen.

Scleroderma-associated Interstitial Lung Disease Since the first placebo-controlled randomized trial published nearly 20 years ago for the treatment of patients with SSc-ILD, evaluating cyclophosphamide vs. placebo, there have been several other randomized studies to guide the management approach, using medications with lower toxicities, in patients with SSc-ILD. https://buff.ly/eKXn2LB

Scleroderma-associated Interstitial Lung Disease Since the first placebo-controlled randomized trial published nearly 20 years ago for the treatment of patients with SSc-ILD, evaluating cyclophosphamide vs. placebo, there have been several other randomized studies to guide the management approach, using medications with lower toxicities, in patients with SSc-ILD. https://buff.ly/eKXn2LB

Scleroderma-associated Interstitial Lung Disease Since the first placebo-controlled randomized trial published nearly 20 years ago for the treatment of patients with SSc-ILD, evaluating cyclophosphamide vs. placebo, there have been several other randomized studies to guide the management approach, using medications with lower toxicities, in patients with SSc-ILD. https://buff.ly/eKXn2LB

Scleroderma-associated Interstitial Lung Disease Since the first placebo-controlled randomized trial published nearly 20 years ago for the treatment of patients with SSc-ILD, evaluating cyclophosphamide vs. placebo, there have been several other randomized studies to guide the management approach, using medications with lower toxicities, in patients with SSc-ILD. https://buff.ly/d05m5F9

A new era of myasthenia gravis (MG) management is unfolding. In this Peer Exchange, James F Howard, Jr, MD, FAAN; Beth Stein, MD; Andrew Gordon, MD; and Ratna Kiran Bhavaraju-Sanka, MD, examine how treatment is rapidly moving beyond conventional symptomatic therapies toward a spectrum of targeted upstream and downstream approaches designed to address the disease at its root. This discussion underscores the importance of early recognition and intervention and shared decision-making that empowers patients to take an active role in their care. Achieving minimal symptom expression is highlighted as a key benchmark that improves daily functioning and reduces the long-term treatment burden. Emerging options such as FcRn inhibitors, complement inhibitors, and agents that target B-cells are opening doors to more personalized strategies, offering the potential for durable disease control and enhanced quality of life. By combining innovative science with patient-centered care, these advances signal a meaningful shift in how clinicians and patients can work together to manage MG today and in the years ahead. Watch Now: https://hubs.li/Q03LKr_h0